Free Trial
→ Trump’s national nightmare is here (From Porter & Company) (Ad)tc pixel

Cybin (OTCMKTS:CYBN) Trading Down 1.6% - What's Next?

Written by MarketBeat
October 17, 2025
Cybin logo with Medical background

Key Points

  • Cybin Inc. shares decreased by 1.6%, trading at $6.10 after previously closing at $6.20, with a total of approximately 521,009 shares exchanged during the session.
  • The company has a market cap of $153.65 million and is focused on developing psychedelic-based therapeutics with several projects in different trial phases.
  • Current clinical trials include CYB003 for major depressive and alcohol use disorders, CYB004 for generalized anxiety disorders, and CYB005 for treating neuroinflammation.
  • Five stocks we like better than Cybin.

Cybin Inc. (OTCMKTS:CYBN - Get Free Report) shares were down 1.6% on Thursday . The company traded as low as $5.95 and last traded at $6.10. Approximately 521,009 shares were traded during trading, an increase of 33% from the average daily volume of 390,822 shares. The stock had previously closed at $6.20.

Cybin Stock Down 1.6%

The company has a 50 day moving average of $6.50 and a 200 day moving average of $7.08. The firm has a market cap of $153.65 million, a price-to-earnings ratio of -32.11 and a beta of 0.63.

About Cybin

(Get Free Report)

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cybin Right Now?

Before you consider Cybin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.

While Cybin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.